Literature DB >> 6109014

Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydopamine treatment.

S Yamada, H I Yamamura, W R Roeske.   

Abstract

To identify and characterize the cardiac alpha-adrenoceptors, a radioreceptor binding assay using the potent alpha adrenergic antagonist, [3H]WB4101 was performed in rat hearts. Specific [3H]WB4101 binding to rat left ventricular homogenates was saturable, reversible and of high affinity (Kd = 0.18 nM) with a Bmax of 2.57 fmol/mg of tissue (27.7 fmol/mg of protein). Adrenergic agonists competed for specific [3H]WB4101 binding in the order: (-)-epinephrine > (-)-norepinephrine greater than (-)-isoproterenol. Stereospecificity of the [3H]WB4101 binding sites was also demonstrated with (-)-epinephrine, (Ki = 90) nM being 270 times as potent as (+)-epinephrine, (K1 = 24 microM). Adrenergic antagonists competed for the binding in the order: WB4101 = prazosin greater than yohimbine greater than (-)-propranolol. WB4101 and prazosin exhibited a markedly greater (2000 times) affinity for [3H]WB4101 binding sites than yohimbine. The affinities (pKi) of alpha agonists and antagonists for [3H]WB4101 binding sites in the rat heart closely correlated with their pharmacological potencies in the heart. Scatchard analysis for [3H]WB4101 binding, performed in five regions from control and 6-hydroxydopamine-treated rat hearts, revealed specific [3H]WB4101 binding (Bmax) significantly greater in the ventricles and intraventricular septae than in atria. At 1 week after 6-hydroxydopamine treatment, there was a significant increase (40%) in the Bmax for [3H]WB4101 binding to ventricles and intraventricular septae without a change in Kd. We conclude: 1) [3H]Wb4101 selectively labels postsynaptic alpha-1 adrenoceptors in the rat heart; 2) there is a definite regional variation for cardiac alpha-1 adrenoceptors; and 3) 6-hydroxydopamine treatment caused a significant increase in the density of alpha-1 adrenoceptors in ventricles and intraventricular septae, compatible with a postsynaptic localization of the [3H]WB4101 binding site.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6109014

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover.

Authors:  J Sallés; S Gascón; A Badia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

2.  Receptor occupancy in myocardium, adrenal cortex, and brain by TH-142177, a novel AT1 receptor antagonist in rats, in relation to its plasma concentration and hypotensive effect.

Authors:  Y Nozawa; H Miyake; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

Review 3.  [Alpha-adrenoceptors in the myocardium: incidence and functional significance].

Authors:  A Mügge
Journal:  Klin Wochenschr       Date:  1985-11-04

4.  An increase in cardiac alpha 1-adrenoceptors following chronic clonidine treatment.

Authors:  S Yamada; H I Yamamura; W R Roeske
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-08       Impact factor: 3.000

5.  Natural vanadium-containing Mt. Fuji ground water improves hypo-activity of liver insulin receptor in Goto-Kakisaki rats.

Authors:  Katsuhiko Kato; Shizuo Yamada; Yuki Ohmori; Tomomi Oki; Eiichi Kawamoto; Kazuhiko Shirama; Yasuo Watanabe
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

6.  Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.

Authors:  Kazufumi Hirano; Ryohei Kimura; Yumi Sugimoto; Jun Yamada; Shinya Uchida; Yasuhiro Kato; Hisakuni Hashimoto; Shizuo Yamada
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

7.  Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.

Authors:  Tomomi Oki; Shuichi Sato; Keiji Miyata; Shizuo Yamada
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

8.  Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats.

Authors:  S Yamada; Y Matsuoka; R Kimura
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

9.  The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats.

Authors:  S Uchida; S Yamada; T Ohkura; M Heshikiri; A Yoshimi; H Shirahase; R Kimura
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

10.  In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPgammaS in rat brain and spinal cord.

Authors:  Shizuo Yamada; Toyofumi Kusaka; Akihiko Urayama; Ryohei Kimura; Yasuo Watanabe
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.